



Contact:

Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx SAB Members publish article in Nature Precision Oncology describing novel approach that can revolutionize precision diagnostics and personalized therapy development.

Beverly, MA, July 21, 2017 – Cellanyx’s SAB members (Grannum R. Sant, Kevin B. Knopf, and David M. Albala) authored a [publication in the journal Nature Precision Oncology](#), discussing Cellanyx’s novel approach to diagnostics that has the potential to revolutionize precision diagnostics and usher in a new era of personalized therapy development. The authors conclude that precision oncology will make great progress in concurrence with the development of a live-cell phenotypic biomarker platform using automated approaches. A comprehensive measurement of live-cell phenotypic biomarkers in cancer represents an innovative and actionable addition to personalized cancer diagnosis, risk stratification, and treatment decision-making.

About Cellanyx

Cellanyx is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

Contact:

Ashok Chander, CEO
ashok@cellanyx.com
978 473 7883

Robert Gottlieb, RMG Associates, LLC

Robertmg52@gmail.com
857 891 9091

###